ArticleBMJ neurology open2026
Non-invasive electrodiagnostic testing for small fibre neuropathy in long COVID-19.
Article in BMJ neurology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Long COVID-19 is associated with a diverse range of debilitating neuropathic and autonomic symptoms that may indicate small fibre neuropathy (SFN). We aimed to assess the utility of multimodal non-invasive electrodiagnostic techniques in evaluating symptomatic individuals. Methods: People with confirmed long COVID-19 who scored >10 points on the Small Fibre Neuropathy Screening List (SFNSL) questionnaire underwent routine neurophysiological testing and a non-invasive SFN protocol of (a) sympathetic skin responses, (b) cutaneous silent period, (c) quantitative thermal thresholds and (d) electrochemical skin conductance. Clinical and demographic information was collected on all individuals who underwent comprehensive physical and psychometric evaluation, including a 6-min walk test, National Aeronautics and Space Administration (NASA) Lean Test, Composite Autonomic Symptom Score-31 (COMPASS-31), European Quality of Life 5-Dimension 5-Level Questionnaire (ED-5D-5L), Modified Fatigue Impact Scale (MFIS) score and Patient Health (depression) Questionnaire (PHQ-9). Results: We assessed nine individuals, of whom three (33%) had neurophysiological evidence of SFN. Median age was 47.8 (range 26.3-67.6) years, duration from COVID-19 infection 23.0 (range 8.5-35.7) months and median SFNSL 34/84. All individuals scored highly in disability measures. Conclusions: Long COVID-19 is associated with functional disability and reduced quality of life. SFN should be considered in all individuals with a suggestive clinical phenotype of neuropathic and autonomic symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.